Grand Pharmaceutical Group

Grand Pharma’s nuclear medicine anti-tumor diagnosis and treatment is one of the Group’s most internationalized business segments. Centered on an integrated diagnosis-and-treatment approach in oncology, the segment has built a pipeline of 16 globally innovative products in the R&D and regulatory registration stages, covering five radionuclides and seven cancer indications. In the early-stage pipeline, RDC products constitute the primary focus, with more than 10 RDC candidates under development. Covering both diagnostic and therapeutic applications, the portfolio provides patients with multi-indication treatment options, multi-modality approaches, and integrated diagnostic and therapeutic solutions, forming a globally leading oncology treatment platform. Its flagship product, SIR-Spheres® Yttrium-90 [90Y] Microsphere Injection (Yigantai®), is the world’s first and currently the only FDA-approved Selective Internal Radiation Therapy (SIRT) product indicated for both unresectable hepatocellular carcinoma (HCC) and liver metastases from colorectal cancer. The product has been recommended by multiple internationally recognized professional organizations and has been incorporated into several authoritative Chinese clinical practice guidelines. LavaTM, an innovative liquid embolic agent, is the first and only FDA-approved liquid embolic agent in the United States for the treatment of peripheral arterial hemorrhage. Driven by the “Go Global” strategy, Grand Pharma is committed to building a globally leading nuclear medicine multinational enterprise (MNC). We are the only international company to achieve full coverage across early research, clinical development, registration, and commercialization in nuclear medicine; the only company with nuclear medicine manufacturing capabilities spanning China, the United States, Europe, and the Asia-Pacific region; and the only nuclear medicine enterprise with a truly global sales network. We have established a fully integrated industrial layout covering R&D, manufacturing, logistics, and commercialization. Supported by R&D hubs based in Boston and Chengdu, manufacturing bases located in Boston, Frankfurt, Singapore and Chengdu, as well as a commercial network covering more than 50 countries and regions worldwide, we have built a global industrial chain for nuclear medicine. The world-class nuclear medicine R&D and manufacturing base located in Wenjiang, Chengdu has obtained a Class A Radiation Safety License issued by the Ministry of Ecology and Environment of China. It is currently one of the most advanced intelligent nuclear medicine facilities globally, featuring the widest range of radioisotopes and the highest level of automation in the industry. The facility operates under an integrated model combining ligands, radioisotopes, technology platforms, and intelligent manufacturing, establishing a fully independent and controllable system from target discovery to clinical application, with 100% independent production. Equipped with a globally leading full-process radiation monitoring system for radiopharmaceuticals, the base delivers nuclear-power-grade safety and unmanned intelligent manufacturing, achieving zero radiation leakage, zero environmental discharge, and zero occupational exposure exceedance, which meets the highest international standards for nuclear facilities. This R&D and manufacturing base will further strengthen the foundation of the company’s nuclear medicine business, accelerate the global deployment of innovative pipelines, promote high-quality development of the nuclear medicine industry, cultivate high-value blockbuster products, and lay a solid foundation for the localization of radiopharmaceuticals.

Cerebro-Cardiovascular Precision Intervention Diagnosis and Treatment

Adhering to the therapeutic philosophy of “intervention without implantation,” the company has established a comprehensive layout across three key directions: access management, chronic disease management, structural heart disease and heart failure, and built a high-end medical device product cluster. Currently, this sector has a portfolio of over 30 products, among which 25 products for access management have been approved for marketing in China. With Boston, Wuhan, Changzhou and Shanghai as core R&D bases, and Boston, Wuhan and Changzhou as core manufacturing bases, the company has formed a fully integrated industrial chain spanning R&D, regulatory registration, manufacturing, and commercialization. To date, the company has completed full construction of both passive and active innovative medical device platforms. The active device R&D and manufacturing base in Wuhan Optics Valley, the passive device R&D and manufacturing base in Changzhou, as well as the Shanghai device R&D center focusing on structural heart disease, have all been put into operation. The company has developed a portfolio of multiple globally innovative and first-in-China products. Among them, the IberisTM multipolar renal artery radiofrequency ablation system is currently the only renal denervation (RDN) product worldwide that has obtained both EU CE certification and the National Medical Products Administration (NMPA) approval, while featuring dual access via radial and femoral arteries, enabling efficient treatment of diseases related to renal artery stenosis. NOVASIGHT & NOVASYNC represent the world’s first commercially available intravascular dual-modality imaging system. In future, the company is committed to building this sector into a leading precision interventional diagnosis and treatment platform for cerebro-cardiovascular diseases both in China and globally.

Grand Pharma has cultivated deep expertise over many years in respiratory and critical care, ENT, and cerebro-cardiovascular fields. It owns multiple high-barrier products and exclusive varieties with leading market shares, supported by strong brand recognition and a solid market position, while maintaining a robust reserve of innovative products.

Respiratory and Critical Care

Adhering to an R&D philosophy that integrates independent R&D with global expansion, Grand Pharma has built a full-cycle product portfolio for chronic airway disease management and a comprehensive critical care pipeline, continuously consolidating its leading position in this field. Its flagship product Qie Nuo® (Eucalyptol, Limonene and Pinene Enteric Capsules), is a nationally exclusive product developed independently and has ranked No.1 by market share for many consecutive years in China’s hospital market for oral antitussive and expectorant medicines. Two globally innovative combination therapies for asthma, Atectura® Breezhaler® and Enerzair® Breezhaler®, represent a new generation of combination inhalation formulations. In November 2025, Ryaltris®, a globally innovative combination nasal spray introduced by Grand Pharma, received marketing approval from the National Medical Products Administration (NMPA). As a novel combination nasal spray containing an antihistamine and a corticosteroid, it is indicated for the treatment of allergic rhinitis in adults and children.

Eye, Nose, and Throat (ENT)

Adhering to a development strategy that integrates traditional Chinese and Western medicine as well as coordinated pharmaceutical and medical device therapies, Grand Pharma continues to enhance a diversified product portfolio featuring the synergistic development of Chinese patent medicines, innovative ophthalmic drugs, and OTC retail products, further strengthening its industry influence and achieving new business breakthroughs. The company’s therapeutic portfolio covers multiple clinical specialties, including ophthalmology, otolaryngology (ENT), and dentistry, encompassing chemical formulations, traditional Chinese medicine formulations, and health products across major categories such as prescription drugs, OTC products, medical devices, and consumer healthcare products. The company has established customer-centric, academically driven professional marketing teams and built a nationwide marketing network. As one of Grand Pharma’s key strategic focus areas, ophthalmology remains at the forefront of the company’s innovation efforts. The company is among the industry leaders in China in terms of ophthalmic innovative drug pipeline deployment, with a portfolio covering traditional Chinese medicines, chemical drugs, OTC products, and medical devices. It has established an integrated ophthalmic ecosystem encompassing prevention, treatment, and eye health management. Hubei Yuanda Tiantianming Pharmaceutical Co., Ltd., Grand Pharma’s ophthalmic manufacturing base, is one of China’s largest manufacturers of ophthalmic formulations. Committed to global ophthalmic innovation, Grand Pharma continues to achieve breakthroughs in R&D and has established a professional, comprehensive, and diversified innovative product portfolio. Its pipeline includes multiple globally innovative candidates, including OC-01 (Varenicline Tartrate Nasal Spray), the world’s first and only innovative therapy for dry eye disease; TP-03 (Lotilaner Ophthalmic Solution, 0.25%), the world’s first and only therapy for Demodex blepharitis; GPN00833, an improved hormone nanosuspension eye drop for post-operative anti-inflammatory and analgesic treatment in ophthalmology; GPN00153 (CBT-001), a globally innovative therapy for pterygium; and GPN00884, a novel ophthalmic formulation designed to slow the progression of myopia in children. Ruizhu® Polyvinyl Alcohol Eye Drops, the company’s flagship ophthalmic product, ranks first in market share within the polyvinyl alcohol category for eye fatigue relief in China’s retail ophthalmic market and ranks among the top three products in the overall eye fatigue segment. Grand Pharma also maintains a strong presence in Chinese patent medicines and ethnic medicines. Its subsidiaries, Grand Beilin (Xi’an) Pharmaceutical Co., Ltd. and Grand Beilin (Qinghai) Pharmaceutical Co., Ltd., collectively own more than 30 exclusive products. Xi’an Beilin’s flagship products include the Jinsang (Golden Throat) Series, Hexue Mingmu Tablets, and Maixuekang Capsules/Enteric-coated Tablets. Qinghai Beilin owns five Tibetan medicine products, including Danzhen Toutong Capsules, four of which are exclusive products.

Cardiovascular & Cerebrovascular Emergency Care

Focusing on both emergency rescue and chronic disease management, Grand Pharma continues to expand and develop clinically needed products for cerebro-cardiovascular and cerebrovascular emergency care and chronic disease management by integrating independent innovation and technological breakthroughs in high-barrier generic drugs. In the emergency care sector, Grand Pharma has been designated as a National Essential Medicines Manufacturing Base, a Strategic Reserve Emergency Medicine Production Enterprise, and a developer of the National Centralized Production Base and Construction Unit for Small-Variety (Shortage) Drugs. The company boasts more than 30 product varieties, among which 14 are included in China’s National Emergency & Critical Care Drug Catalogue and 16 are listed in the National Shortage Drug Catalogue. Its pipeline ranks among the industry leaders, covering three major emergency scenarios: in-hospital emergency care, pre-hospital emergency care and community emergency response. It continuously provides a multi-scenario, multi-option, safe and effective product portfolio for patients with acute cerebro-cardiovascular and cerebrovascular emergencies. In the field of chronic disease management, flagship products including Nengqilang® (Coenzyme Q10 Tablets), Limeitong® (Eplerenone Tablets), and Hexinshuang®/Hebeishuang® (Diltiazem Hydrochloride series) continue to lead the market. The globally innovative product Youminsu® Neffy® epinephrine nasal spray is the first non-injectable therapy approved by the U.S. FDA in nearly 35 years for the treatment of Type I allergic reactions, including anaphylaxis. Adopting an innovative nasal delivery route, it features ease of use and portability, and helps patients avoid injection pain and needle phobia.

Our API segment has developed a robust and diversified product pipeline with a strong cluster-based portfolio advantage, combining high-volume APIs with specialty APIs, supported by a global sales network. As a critical upstream component of our integrated API–formulation supply chain, we now operate multiple modern API manufacturing bases featuring advanced equipment, industry-leading processes, strong industrialization capabilities, and rigorous quality control systems. Focusing on five key therapeutic areas—cardiovascular & cerebrovascular, anti-infective, analgesic & antipyretic, gastrointestinal, and anticancer—we support the full lifecycle of drug product development and manufacturing within our pharmaceutical technology business. This ensures high standards and consistency in finished formulations, enabling true integration of upstream and downstream industrial advantages.

mRNA platform

With Nanjing Aurabio Biotechnology Co., Ltd. as its core, the company has built a world-leading mRNA technology platform, with its product pipeline focusing on two major diseases: oncology and infectious diseases. ARC01, a therapeutic mRNA vaccine for HPV16-positive solid tumors as one of our core pipeline candidates, obtained Investigational New Drug (IND) clearance in 2024, and its clinical study was officially launched. To date, the project has successfully completed dose escalation across multiple dose groups. Partial responses have been observed in several enrolled patients, and the candidate is expected to become the world’s first therapeutic mRNA vaccine for cervical cancer. In 2025, Aurabio entered into a strategic cooperation with Hubei Jiangxia Laboratory to jointly advance the R&D of ARP02, a therapeutic vaccine against herpes simplex virus. At present, the two parties are steadily conducting collaborative preclinical studies and launching Investigator-Initiated Trial (IIT) clinical study in parallel to accelerate the translation of research achievements.

We are a leading global supplier of high quality amino acids, committed to technological innovation and stringent quality assurance. We place strong emphasis on technological innovation and the development of a high-standard quality assurance system. We have obtained comprehensive domestic and international quality certifications and have been recognized with multiple national-level honors, including National Green Factory, National Manufacturing Single Champion Demonstration Enterprise, National Specialized and Innovative Enterprise, and National Intellectual Property Demonstration Enterprise.

Our biotechnology R&D team comprises more than 90 researchers and has secured over 300 invention patents. We have led or participated in the formulation of more than 70 national, industry, and association standards, with nearly 50 standards already officially issued. We have developed nearly 50 types of amino acids and their derivatives and hold 26 API registration approvals for amino acids, making us the pharmaceutical company with the largest number of registered amino acid APIs in China. Our amino acid sales network covers more than 140 countries and regions worldwide. We have long served high-quality domestic and international clients, including Fortune Global 500 companies, and have established stable, long-term cooperative relationships across the upstream and downstream sectors of the industrial chain. Our global brand recognition and market reputation rank among the industry’s leading positions.